Risk Management



Compounded Drugs and Off-Label Use

Welcome to OMIC’s Compounded Drugs and Off-Label Use risk management resource library. We are committed to providing you with the resources and templates necessary to adequately inform your patients about the risks, benefits, and alternatives of this procedure.

Compounded Products: Use, Regulation, and Risk
Liability and Coverage for Contaminated-Product Claims
Reduce the Risks of Compounded Drugs
Read the Label Carefully: How Ads for Off-Label Drugs and Devices Could Harm Your Practice
Hotline Q&A: Standing Order Medications
Medical Implications of Using Off-Label Drugs and Devices
Case Study: Lack of Informed Consent for Use of a Research Drug
Informed Consent for Off-Label Use of a Drug or Device
When FDA Leaves Doctors to Their Own Devices
Responding to “Dear Healthcare Provider” Letters

2013 Update: New Regulations For Compounding Drugs Coming Into Focus…

Visit OMIC’s Drugs and Devices library to view other resources for Compounded Drugs and Off-Label Use including risk management articles, closed claim studies, and recommendation and procedure guides.

See also: Advertising resources.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment



scales

Six reasons OMIC is the best choice for ophthalmologists in America.

#3. Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to your carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC’s base rates have consistently averaged approximately 15% lower than multispecialty carriers in the U.S.

61864684